Wall Street brokerages forecast that Cara Therapeutics Inc (NASDAQ:CARA) will announce earnings per share (EPS) of ($0.59) for the current quarter, Zacks reports. Five analysts have made estimates for Cara Therapeutics’ earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.49). Cara Therapeutics reported earnings of ($0.51) per share during the same quarter last year, which would indicate a negative year over year growth rate of 15.7%. The firm is expected to announce its next earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Cara Therapeutics will report full-year earnings of ($2.32) per share for the current year, with EPS estimates ranging from ($2.57) to ($2.08). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.11) per share, with EPS estimates ranging from ($3.01) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Cara Therapeutics.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.03. Cara Therapeutics had a negative net margin of 420.97% and a negative return on equity of 68.36%. The firm had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.14 million.
In other news, CEO Derek T. Chalmers sold 5,528 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $21.42, for a total value of $118,409.76. Following the completion of the sale, the chief executive officer now directly owns 963,996 shares of the company’s stock, valued at approximately $20,648,794.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mani Mohindru sold 37,431 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $25.00, for a total transaction of $935,775.00. Following the completion of the sale, the chief financial officer now directly owns 51,294 shares of the company’s stock, valued at $1,282,350. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,848 shares of company stock valued at $2,844,442. Company insiders own 5.80% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in CARA. TCG Advisors LP acquired a new stake in Cara Therapeutics during the first quarter valued at approximately $30,000. Aperio Group LLC acquired a new stake in Cara Therapeutics during the second quarter valued at approximately $88,000. BNP Paribas Arbitrage SA lifted its stake in Cara Therapeutics by 67,680.0% during the first quarter. BNP Paribas Arbitrage SA now owns 6,778 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 6,768 shares during the last quarter. Knott David M acquired a new stake in Cara Therapeutics during the first quarter valued at approximately $140,000. Finally, Sfmg LLC acquired a new stake in Cara Therapeutics during the second quarter valued at approximately $200,000. 58.03% of the stock is owned by institutional investors and hedge funds.
Shares of CARA stock opened at $22.93 on Friday. Cara Therapeutics has a 12 month low of $12.19 and a 12 month high of $27.55. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $23.61 and its two-hundred day moving average price is $20.00.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.